Arkolith/Insider Trading/SBTX/Form 4

Shawver Laura

Chief Executive Officer, DirectorSilverback Therapeutics, Inc. (SBTX) · full profile →Form 4 · filed Feb 2, 2022
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
3
1 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 1, 2022Grant(A)28K—$0107K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 1, 2022Grant(A)105K—$0105K
Feb 1, 2022Grant(A)165K—$0165K

Transaction Codes

A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001209191-22-006435) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML